Recombinant Marek’s disease virus type 1 provides full protection against H9N2 influenza A virus in chickens

IF 2.4 2区农林科学 Q3 MICROBIOLOGY

Veterinary microbiology Pub Date : 2024-09-02 DOI:10.1016/j.vetmic.2024.110242

Yuntong Chen, Qingqing Yu, Wenrui Fan, Xianying Zeng, Zibo Zhang, Guobin Tian, Changjun Liu, Hongmei Bao, Longbo Wu, Yanping Zhang, Yongzhen Liu, Suyan Wang, Hongyu Cui, Yulu Duan, Hualan Chen, Yulong Gao

{"title":"Recombinant Marek’s disease virus type 1 provides full protection against H9N2 influenza A virus in chickens","authors":"Yuntong Chen, Qingqing Yu, Wenrui Fan, Xianying Zeng, Zibo Zhang, Guobin Tian, Changjun Liu, Hongmei Bao, Longbo Wu, Yanping Zhang, Yongzhen Liu, Suyan Wang, Hongyu Cui, Yulu Duan, Hualan Chen, Yulong Gao","doi":"10.1016/j.vetmic.2024.110242","DOIUrl":null,"url":null,"abstract":"<div><p>The H9N2 subtype of the avian influenza virus (AIV) poses a significant threat to the poultry industry and human health. Recombinant vaccines are the preferred method of controlling H9N2 AIV, and Marek’s disease virus (MDV) is the ideal vector for recombinant vaccines. During this study, we constructed two recombinant MDV type 1 strains that carry the hemagglutinin (HA) gene of AIV to provide dual protection against both AIV and MDV. To assess the effects of different MDV insertion sites on the protective efficacy of H9N2 AIV, the HA gene of H9N2 AIV was inserted in UL41 and US2 of the MDV type 1 vector backbone to obtain recombinant viruses rMDV-UL41/HA and rMDV-US2/HA, respectively. An indirect immunofluorescence assay showed sustained expression of HA protein in both recombinant viruses. Additionally, the insertion of the HA gene in UL41 and US2 did not affect MDV replication in cell cultures. After immunization of specific pathogen-free chickens, although both the rMDV-UL41/HA and rMDV-US2/HA groups exhibited similar levels of hemagglutination inhibition antibody titers, only the rMDV-UL41/HA group provided complete protection against the H9N2 AIV challenge, and also offered complete protection against challenge with MDV. These results demonstrated that rMDV-UL41/HA could be used as a promising bivalent vaccine strain against both H9N2 avian influenza and Marek’s disease in chickens.</p></div>","PeriodicalId":23551,"journal":{"name":"Veterinary microbiology","volume":"298 ","pages":"Article 110242"},"PeriodicalIF":2.4000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary microbiology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378113524002645","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The H9N2 subtype of the avian influenza virus (AIV) poses a significant threat to the poultry industry and human health. Recombinant vaccines are the preferred method of controlling H9N2 AIV, and Marek’s disease virus (MDV) is the ideal vector for recombinant vaccines. During this study, we constructed two recombinant MDV type 1 strains that carry the hemagglutinin (HA) gene of AIV to provide dual protection against both AIV and MDV. To assess the effects of different MDV insertion sites on the protective efficacy of H9N2 AIV, the HA gene of H9N2 AIV was inserted in UL41 and US2 of the MDV type 1 vector backbone to obtain recombinant viruses rMDV-UL41/HA and rMDV-US2/HA, respectively. An indirect immunofluorescence assay showed sustained expression of HA protein in both recombinant viruses. Additionally, the insertion of the HA gene in UL41 and US2 did not affect MDV replication in cell cultures. After immunization of specific pathogen-free chickens, although both the rMDV-UL41/HA and rMDV-US2/HA groups exhibited similar levels of hemagglutination inhibition antibody titers, only the rMDV-UL41/HA group provided complete protection against the H9N2 AIV challenge, and also offered complete protection against challenge with MDV. These results demonstrated that rMDV-UL41/HA could be used as a promising bivalent vaccine strain against both H9N2 avian influenza and Marek’s disease in chickens.

查看原文本刊更多论文

重组马立克氏病 1 型病毒可为鸡提供对 H9N2 甲型流感病毒的全面保护。

H9N2 亚型禽流感病毒 (AIV) 对家禽业和人类健康构成了严重威胁。重组疫苗是控制 H9N2 AIV 的首选方法，而马立克氏病病毒（MDV）是重组疫苗的理想载体。在这项研究中，我们构建了两种携带甲型禽流感病毒血凝素（HA）基因的重组 MDV 1 型毒株，以提供对甲型禽流感病毒和 MDV 的双重保护。为了评估不同MDV插入位点对H9N2 AIV保护效力的影响，我们将H9N2 AIV的HA基因分别插入MDV 1型载体骨架的UL41和US2，得到重组病毒rMDV-UL41/HA和rMDV-US2/HA。间接免疫荧光检测显示，这两种重组病毒中都有 HA 蛋白的持续表达。此外，在 UL41 和 US2 中插入 HA 基因不会影响 MDV 在细胞培养物中的复制。在对特定的无病原体鸡进行免疫后，虽然 rMDV-UL41/HA 组和 rMDV-US2/HA 组都表现出了相似水平的血凝抑制抗体滴度，但只有 rMDV-UL41/HA 组在 H9N2 AIV 挑战中提供了完全的保护，并且在 MDV 挑战中也提供了完全的保护。这些结果表明，rMDV-UL41/HA 可作为一种很有前景的二价疫苗毒株，用于预防鸡的 H9N2 禽流感和马立克氏病。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary microbiology 农林科学-兽医学

CiteScore

5.90

自引率

6.10%

发文量

221

审稿时长

52 days

期刊介绍： Veterinary Microbiology is concerned with microbial (bacterial, fungal, viral) diseases of domesticated vertebrate animals (livestock, companion animals, fur-bearing animals, game, poultry, fish) that supply food, other useful products or companionship. In addition, Microbial diseases of wild animals living in captivity, or as members of the feral fauna will also be considered if the infections are of interest because of their interrelation with humans (zoonoses) and/or domestic animals. Studies of antimicrobial resistance are also included, provided that the results represent a substantial advance in knowledge. Authors are strongly encouraged to read - prior to submission - the Editorials (''Scope or cope'' and ''Scope or cope II'') published previously in the journal. The Editors reserve the right to suggest submission to another journal for those papers which they feel would be more appropriate for consideration by that journal. Original research papers of high quality and novelty on aspects of control, host response, molecular biology, pathogenesis, prevention, and treatment of microbial diseases of animals are published. Papers dealing primarily with immunology, epidemiology, molecular biology and antiviral or microbial agents will only be considered if they demonstrate a clear impact on a disease. Papers focusing solely on diagnostic techniques (such as another PCR protocol or ELISA) will not be published - focus should be on a microorganism and not on a particular technique. Papers only reporting microbial sequences, transcriptomics data, or proteomics data will not be considered unless the results represent a substantial advance in knowledge. Drug trial papers will be considered if they have general application or significance. Papers on the identification of microorganisms will also be considered, but detailed taxonomic studies do not fall within the scope of the journal. Case reports will not be published, unless they have general application or contain novel aspects. Papers of geographically limited interest, which repeat what had been established elsewhere will not be considered. The readership of the journal is global.